ID: ALA5202120

Max Phase: Preclinical

Molecular Formula: C18H28N8

Molecular Weight: 356.48

Associated Items:

Representations

Canonical SMILES:  Nc1nc(N)nc(NCCCCCN2CCN(c3ccccc3)CC2)n1

Standard InChI:  InChI=1S/C18H28N8/c19-16-22-17(20)24-18(23-16)21-9-5-2-6-10-25-11-13-26(14-12-25)15-7-3-1-4-8-15/h1,3-4,7-8H,2,5-6,9-14H2,(H5,19,20,21,22,23,24)

Standard InChI Key:  CEYHRGCVTQARPC-UHFFFAOYSA-N

Associated Targets(Human)

Serotonin 1a (5-HT1a) receptor 14969 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serotonin 2a (5-HT2a) receptor 14758 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serotonin 6 (5-HT6) receptor 9749 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serotonin 7 (5-HT7) receptor 5576 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Dopamine D2 receptor 23596 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 356.48Molecular Weight (Monoisotopic): 356.2437AlogP: 1.44#Rotatable Bonds: 8
Polar Surface Area: 109.22Molecular Species: BASEHBA: 8HBD: 3
#RO5 Violations: 0HBA (Lipinski): 8HBD (Lipinski): 5#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 9.45CX LogP: 2.49CX LogD: -0.37
Aromatic Rings: 2Heavy Atoms: 26QED Weighted: 0.61Np Likeness Score: -1.49

References

1. Kułaga D, Drabczyk AK, Satała G, Latacz G, Rózga K, Plażuk D, Jaśkowska J..  (2022)  Design and synthesis of new potent 5-HT7 receptor ligands as a candidate for the treatment of central nervous system diseases.,  227  [PMID:34710746] [10.1016/j.ejmech.2021.113931]

Source